参松养心胶囊联合美托洛尔治疗冠心病合并室性心律失常的效果观察

目的分析参松养心胶囊联合美托洛尔治疗冠心病伴室性心律失常的效果。 方法将100例冠心病伴室性心律失常患者根据随机数表法分为对照组与观察组，各50例。全部患者均接受基础治疗，在此基础上给予对照组患者美托洛尔胶囊口服，观察组在对照组用药基础上联合使用参松养心胶囊，全部患者均连续用药8周。分别于治疗前、治疗4周、治疗8周时为患者实施常规12导联心电图检查与24 h动态心电图检查，检测并比较两组患者治疗各时点的QTc离散度(QTcd)、短阵室速次数、室性期前收缩次数；记录患者治疗期间不良反应发生情况。 结果观察组治疗总有效率高于对照组，差异有统计学意义(P<0.05)；治疗4周、治疗8周，两组患者QTcd值、短阵室速次数、室性期前收缩次数均较治疗前降低，且观察组降低幅度高于对照组，差异有统计学意义(P<0.05)；两组患者药物治疗期间不良反应发生率比较，差异无统计学意义(P>0.05)。 结论采用美托洛尔联合参松养心胶囊治疗冠心病伴室性心律失常，患者心脏电生理特性显著改善，动作电位延长，治疗效果优于单用美托洛尔，且安全性好。

Effect of Shensong Yangxin capsule combined with metoprolol in the treatment of coronary heart disease complicated with ventricular arrhythmia

ObjectiveTo analyze the effect of Shensong Yangxin capsule combined with metoprolol in the treatment of coronary heart disease complicated with ventricular arrhythmia. MethodsA total of 100 patients with coronary heart disease and ventricular arrhythmia were divided into control group and observation group according to random number table method, 50 cases in each group. All patients received basic treatment. On this basis, the control group was given metoprolol capsule orally. The observation group was given Shensong Yangxin capsule on the basis of the control group. All patients were treated for 8 weeks. Routine 12-lead electrocardiogram and 24-hour dynamic electrocardiogram were performed before treatment, 4 weeks after treatment and 8 weeks after treatment, respectively. The QTc dispersion (QTcd), short ventricular tachycardia (VT) and ventricular premature contraction (VPC) were detected and compared between the two groups at each time point of treatment. The occurrence of adverse reactions during treatment was recorded. ResultsThe total effective rate of the observation group was higher than that of the control group (P<0.05). After 4 weeks and 8 weeks of treatment, the QTcd value, the number of short ventricular tachycardia and the number of premature ventricular contractions of the two groups were lower than those before treatment, and the decrease of the observation group was higher than that of the control group (P<0.05). The incidence of adverse reactions of the two groups was lower than that of the control group (P<0.05). There was no significant difference (P>0.05). ConclusionUsing metoprolol combined with Shensong Yangxin capsule in the treatment of coronary heart disease with ventricular arrhythmia, the electrophysiological characteristics of the heart were significantly improved, action potential was prolonged, the therapeutic effect was better than metoprolol alone, and the safety was good.